<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>STTR Phase I:  A therapeutic molecule for COVID-19</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>02/15/2021</AwardEffectiveDate>
<AwardExpirationDate>01/31/2022</AwardExpirationDate>
<AwardTotalIntnAmount>256000.00</AwardTotalIntnAmount>
<AwardAmount>256000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Kaitlin Bratlie</SignBlockName>
<PO_EMAI>kbratlie@nsf.gov</PO_EMAI>
<PO_PHON>7032922638</PO_PHON>
</ProgramOfficer>
<AbstractNarration>The broader impact of this Small Business Technology Transfer (STTR) Phase I project is to provide a therapeutic solution for coronavirus pandemics.  Coronaviruses have been implicated in several outbreaks, including prior SARS and MERS. The proposed therapeutic will inhibit the virusâ€™s ability to replicate and elicit the body's immune system to kill the virus.  In addition, this research can be applied to solutions for other viruses including RSV, hepatitis B and HIV/AIDS.&lt;br/&gt;&lt;br/&gt;The proposed project will advance a method integrating vaccines, small molecule inhibitors, and antibodies. This project will identify a small molecule that targets and binds to the virus, then link it to a small payload that signals the body's immune system.  This project will identify and develop a targeting molecule that can bind effectively to multiple strains of the coronavirus and a payload that promotes an appropriate immune response.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>02/05/2021</MinAmdLetterDate>
<MaxAmdLetterDate>02/05/2021</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2035422</AwardID>
<Investigator>
<FirstName>Martin</FirstName>
<LastName>Low</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Martin Low</PI_FULL_NAME>
<EmailAddress>martin.low@eradivir.com</EmailAddress>
<PI_PHON>4847441500</PI_PHON>
<NSF_ID>000826726</NSF_ID>
<StartDate>02/05/2021</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Investigator>
<FirstName>Madduri</FirstName>
<LastName>Srinivasarao</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Madduri Srinivasarao</PI_FULL_NAME>
<EmailAddress>msriniva@purdue.edu</EmailAddress>
<PI_PHON>7655326859</PI_PHON>
<NSF_ID>000828728</NSF_ID>
<StartDate>02/05/2021</StartDate>
<EndDate/>
<RoleCode>Co-Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>ERADIVIR, INC.</Name>
<CityName>WEST LAFAYETTE</CityName>
<CountyName>TIPPECANOE</CountyName>
<ZipCode>479064182</ZipCode>
<PhoneNumber>4847441500</PhoneNumber>
<StreetAddress>1281 WIN HENTSCHEL BLVD</StreetAddress>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<StateCode>IN</StateCode>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>IN04</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>117493170</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>ERADIVIR, INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[ERADIVIR, INC.]]></Name>
<CityName>West Lafayette</CityName>
<CountyName>TIPPECANOE</CountyName>
<StateCode>IN</StateCode>
<ZipCode>479064182</ZipCode>
<StreetAddress><![CDATA[1281 Win Hentschel]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>IN04</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1505</Code>
<Text>STTR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>6883</Code>
<Text>CHEMISTRY OF LIFE PROCESSES</Text>
</ProgramReference>
<Appropriation>
<Code>0121</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2021~256000</FUND_OBLG>
</Award>
</rootTag>
